This program will look at the correct timing and modality of transition from intravenous to oral platelet inhibition in patients. Lessons learned from the PHOENIX and CHAMPION study and the outcomes of establishing potent P2Y12 inhibition with medication will be discussed.
In this webcast experts in the field of cardiology discuss the future of low risk TAVR procedures and new criteria for TAVR use in patients, including STS scores, frailty, and disability for enrollment in a low risk trial.
During this webcast, experts in the field discuss results from the latest stent trials. Find out about data from the trials and how it guides current practice, as well as the future of the next generation DES.
In this webcast, Dr. Vinod Thourani, Dr. Howard Herrmann, and Dr. Michael Reardon discuss the latest findings on the expanded indications of transcatheter aortic valve replacement (TAVR) in intermediate risk and high risk patients.